Aptevo to Showcase Multispecific Platform at SITC 2026 Meeting

SEATTLE, October 14, 2026 /CourierPR/ -- Aptevo Therapeutics, a clinical-stage biotechnology company focused on developing novel multispecific immunotherapies for cancer, is set to showcase its multispecific platform at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting. The presentation, scheduled for November 4-8, 2026, at the Phoenix Convention Center in Phoenix, Arizona, will highlight the company’s broader CD40-directed multispecific portfolio and its approach to bringing together two critical arms of the immune system, innate and adaptive immunity, within the tumor microenvironment.

Aptevo’s platform is designed to coordinate innate and adaptive immune activity within the tumor microenvironment. This approach aims to address the challenges posed by solid tumors, which can suppress or disrupt anti-tumor immune responses. By localizing immune activation to the tumor, Aptevo’s technology seeks to promote a more complete anti-tumor response. The company’s multispecific technology combines multiple distinct targeting or immune-modulating functions within a single therapeutic molecule. This approach is intended to enable coordinated, tumor-directed immune activity while addressing mechanisms within the tumor microenvironment that can limit the effectiveness of cancer immunotherapies.

Mary Janatpour, PhD, Senior Vice President and Chief Scientific Officer of Aptevo, expressed enthusiasm about the progress being shared.

The abstract number for the presentation is 1060. The presentation will feature Aptevo’s broader CD40-directed multispecific portfolio and the company’s approach to engaging both innate and adaptive immunity within the tumor microenvironment.

The company’s pipeline candidates are created from its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies. These candidates are designed to engage the immune system through differentiated mechanisms of action, with the potential to improve treatment outcomes and transform the lives of cancer patients. Aptevo’s platform is intended to enable coordinated, tumor-directed immune activity while addressing mechanisms within the tumor microenvironment that can limit the effectiveness of cancer immunotherapies.

This presentation at the SITC 2026 Annual Meeting underscores Aptevo’s commitment to advancing the field of cancer immunotherapy. The company’s multispecific platform represents a significant step in the development of next-generation immunotherapies, designed to address some of the most persistent challenges in solid tumors.